Eli Lilly presented Phase 3 trial data showing its experimental weekly injection retatrutide reduced moderate-to-severe obstructive sleep apnea by 60.6 percent in adults with obesity. Presented in New Orleans, the findings also revealed the triple-hormone receptor drug eased knee osteoarthritis pain by up to 73.1 percent.
Trial Outcomes for Retatrutide in Obesity and Associated Conditions
Drugmaker Eli Lilly presented trial results to medical professionals detailing the performance of retatrutide, its experimental next-generation medication targeting multiple metabolic receptors. In a Phase 3 trial evaluating adults with obesity, a weekly injection of the drug curbed the severity of moderate-to-severe obstructive sleep apnea by 60.6 per cent.
Beyond sleep apnea improvements, the same trial demonstrated that retatrutide reduced knee osteoarthritis pain by up to 73.1 per cent. These findings were shared at an American Diabetes Association conference in New Orleans, expanding upon earlier data disclosures from the Indiana-based company.
Broader Metabolic Effects and Cardiovascular Safety Data
Earlier disclosures from Eli Lilly showed that patients with obesity achieved a 28 per cent reduction in body weight while taking the drug, while adults managing type 2 diabetes experienced significant drops in blood sugar levels. Detailed results published in the Lancet noted that 2 per cent of participants with diabetes who received the lowest dose experienced major adverse cardiovascular events, though the publication stated those events were not necessarily caused by the treatment.
Retatrutide is categorized as a “triple G” medication designed to stimulate three distinct hormone receptors: GLP-1, a second obesity-related hormone known as GIP, and glucagon. This multi-pronged mechanism places the company in intense competition with rivals like Denmark-based Novo Nordisk to capture shares of the expanding market for diabetes and weight management therapeutics.
Cellular Discoveries Behind Oral Diabetes Treatments
While experimental injectable therapies target multiple hormone receptors, researchers continue to explore how established oral medications influence metabolism. A study published in Nature Metabolism investigated metformin, a widely prescribed medication used to control blood sugar levels in patients with type 2 diabetes. Historically, the mechanism behind the moderate weight loss observed in patients taking metformin—typically a 2 per cent to 3 per cent reduction in body weight within the first year—remained unclear.
Joint research conducted by teams at Stanford Medicine and Harvard Medical School identified an “anti-hunger” molecule called lac-phe, which is produced after vigorous exercise. When researchers administered metformin to laboratory mice, the animals exhibited increased blood levels of lac-phe, reduced food intake, and lost about 2 grams of body weight during a nine-day experiment. Analysis of stored blood plasma samples from patients with type 2 diabetes and participants in a large atherosclerosis study confirmed significant increases in lac-phe following metformin treatment.
“Until now, the way metformin, which is prescribed to control blood sugar levels, also brings about weight loss has been unclear. Now we know that it is acting through the same pathway as vigorous exercise to reduce hunger. Understanding how these pathways are controlled may lead to viable strategies to lower body mass and improve health in millions of people.”
Jonathan Long, PhD, assistant professor of pathology at Stanford Medicine
Further investigation revealed that lac-phe is synthesized by intestinal epithelial cells in animals, creating an avenue of gut-to-brain communication that researchers suggest could guide the development of optimized oral therapies for weight management.
